Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Reza Elaidi; A. Harbaoui; B. Beuselinck; J. C. Eymard; A. Bamias; E. De Guillebon; C. Porta; Y. Vano; C. Linassier; P. R. Debruyne; M. Gross-Goupil; A. Ravaud; M. Aitelhaj; G. Marret; S. Oudard

doi:10.1093/annonc/mdu552

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Reza Elaidi^*
, A. Harbaoui
, B. Beuselinck
, J. C. Eymard
, A. Bamias
, E. De Guillebon
, C. Porta
, Y. Vano
, C. Linassier
, P. R. Debruyne
, M. Gross-Goupil
, A. Ravaud
, M. Aitelhaj
, G. Marret
, S. Oudard

^*Corresponding author for this work

Georges Pompidou European Hospital
Association Pour la Recherche de The´rapeutiques Innovantes en Cance´rologie
Hôpital Saint-André
KU Leuven
Centre Joliot Curie
National and Kapodistrian University of Athens
CHU de Poitiers
IRCCS Fondazione Policlinico San Matteo - Pavia
Centre Antoine Lacassagne
Centre Hospitalier Régional Universitaire de Tours
General Hospital Groeninge
University of Greenwich
Rene´ Descartes Faculty

Research output: Contribution to journal › Article › peer-review

Abstract

In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.

Original language	English
Pages (from-to)	378-385
Number of pages	8
Journal	Annals of Oncology
Volume	26
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mdu552
Publication status	Published - 1 Feb 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology

Keywords

Kidney cancer
Mammalian target of rapamycin (mTOR)
Sequence
Tyrosine kinase inhibitor

Access to Document

10.1093/annonc/mdu552

Cite this

Elaidi, R., Harbaoui, A., Beuselinck, B., Eymard, J. C., Bamias, A., De Guillebon, E., Porta, C., Vano, Y., Linassier, C., Debruyne, P. R., Gross-Goupil, M., Ravaud, A., Aitelhaj, M., Marret, G., & Oudard, S. (2015). Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Annals of Oncology, 26(2), 378-385. https://doi.org/10.1093/annonc/mdu552

@article{06bd683d79fa43e796fc599a922163a0,

title = "Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma",

abstract = "In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.",

keywords = "Kidney cancer, Mammalian target of rapamycin (mTOR), Sequence, Tyrosine kinase inhibitor",

author = "Reza Elaidi and A. Harbaoui and B. Beuselinck and Eymard, \{J. C.\} and A. Bamias and \{De Guillebon\}, E. and C. Porta and Y. Vano and C. Linassier and Debruyne, \{P. R.\} and M. Gross-Goupil and A. Ravaud and M. Aitelhaj and G. Marret and S. Oudard",

year = "2015",

month = feb,

day = "1",

doi = "10.1093/annonc/mdu552",

language = "English",

volume = "26",

pages = "378--385",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "2",

}

Elaidi, R, Harbaoui, A, Beuselinck, B, Eymard, JC, Bamias, A, De Guillebon, E, Porta, C, Vano, Y, Linassier, C, Debruyne, PR, Gross-Goupil, M, Ravaud, A, Aitelhaj, M, Marret, G & Oudard, S 2015, 'Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma', Annals of Oncology, vol. 26, no. 2, pp. 378-385. https://doi.org/10.1093/annonc/mdu552

TY - JOUR

T1 - Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

AU - Elaidi, Reza

AU - Harbaoui, A.

AU - Beuselinck, B.

AU - Eymard, J. C.

AU - Bamias, A.

AU - De Guillebon, E.

AU - Porta, C.

AU - Vano, Y.

AU - Linassier, C.

AU - Debruyne, P. R.

AU - Gross-Goupil, M.

AU - Ravaud, A.

AU - Aitelhaj, M.

AU - Marret, G.

AU - Oudard, S.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.

AB - In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.

KW - Kidney cancer

KW - Mammalian target of rapamycin (mTOR)

KW - Sequence

KW - Tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/84925304746

U2 - 10.1093/annonc/mdu552

DO - 10.1093/annonc/mdu552

M3 - Article

C2 - 25467013

AN - SCOPUS:84925304746

SN - 0923-7534

VL - 26

SP - 378

EP - 385

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Abstract

UN SDGs

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this